Your Cart is Empty
BUY 1 GET 1 FREE · AUTO APPLIES AT CHECKOUT
PREGNANCY SAFETY NOTICE | IMPORTANT SAFETY NOTICE: The FDA and major medical organizations including ACOG advise against using CBD, THC, or any cannabis-derived product during pregnancy or while breastfeeding. CBD safety in pregnancy has not been established, and preclinical research raises concerns about effects on fetal development. PureCraft CBD products are not intended for use during pregnancy or while breastfeeding. This article is for informational purposes only and does not constitute medical advice. Always consult your obstetrician before using any supplement during pregnancy. The FDA has not approved CBD for any use in pregnancy.
Pregnancy is one of the most important contexts in which to be honest about what we know, what we don't know, and what the prudent course of action is given uncertainty. For CBDin pregnancy, the answer is straightforward: the FDA, the American College of Obstetricians and Gynecologists (ACOG), and every major medical authority recommends avoiding CBD during pregnancy and breastfeeding. PureCraft's products are not intended for pregnant or breastfeeding individuals.
The purpose of this post is not to make a case for CBD in pregnancy — there is no such case to make responsibly. The purpose is to explain the reasoning behind this recommendation, provide an accurate account of what the research actually shows, address why people ask this question (pregnancy symptoms that drive CBD interest are real and deserve real alternatives), and link to the post-pregnancy context where CBD's safety profile returns to favorable territory.
For the postpartum context where CBD's risks are different, seeCBD for Postpartum Anxiety: What You Need to Know. The postpartum period has its own medical considerations distinct from pregnancy and breastfeeding.
In 2019, the FDA issued an updated warning advising against CBD use during pregnancy and breastfeeding.The FDA's guidance specifically states: 'CBD has been shown to pass through the placenta… we strongly advise against the use of CBD, THC, or marijuana in any form during pregnancy or while breastfeeding.'
The American College of Obstetricians and Gynecologists (ACOG)similarly advises that women who are pregnant or contemplating pregnancy should be encouraged to discontinue marijuana use — and specifically notes that the lack of safety data for CBD in pregnancy means the precautionary principle applies. Their position is not that CBD is proven harmful; it is that safety has not been established, and the developing fetus is not an appropriate context for uncertainty.
PureCraft's position aligns completely with this guidance.Our products are not intended for use during pregnancy or breastfeeding. If you are pregnant and have questions about symptom management, your obstetrician is the right resource.
The reason CBD in pregnancy is a particular concern — not just the same general 'insufficient safety data' concern that applies to most supplements — is that the endocannabinoid system plays an active, documented role in fetal brain development.
CB1 receptors appear in the human fetal brain as early as the 14th week of gestation. During development, endocannabinoid signaling guides neuronal migration, axonal growth, synapse formation, and the establishment of neurotransmitter systems. A2013 review in Neuropharmacology established that the endocannabinoid system is not merely present in the fetal brain — it is actively directing critical developmental processes that cannot be easily 'redone' if disrupted.
CBD's interaction with the ECS — including FAAH inhibition (altering endocannabinoid tone), CB1 negative allosteric modulation, and CB2 engagement — introduces exogenous cannabinoid signaling into a developing system where endocannabinoid activity is performing irreplaceable developmental functions. Even if CBD doesn't produce the same CB1 agonist effects as THC, its modulation of the ECS during a period of critical ECS-directed development is reason for serious caution.
|
Research Type |
What Was Found |
Concerning? |
Limitation / Context |
|
Animal studies — fetal brain development |
CBD exposure during prenatal period altered CB1 receptor density in offspring brain; changes in anxiety behavior and stress response documented in offspring |
Yes — ECS plays a critical role in fetal brain development; disruption has potential long-term consequences |
Animal models; doses often above human supplement equivalent; direct human translation uncertain but precautionary principle applies |
|
Animal studies — reproductive outcomes |
High-dose CBD produced reduced litter sizes, altered sex ratios, and developmental delays in some rodent studies |
Yes at high doses |
Very high doses in some studies; dose dependency unclear; human reproductive impact not established but cannot be dismissed |
|
Placenta permeability |
CBD crosses the placental barrier — both in animal models and in limited human tissue studies; reach the fetal compartment confirmed |
Yes — fetal exposure is confirmed, not theoretical |
Degree of fetal exposure depends on maternal dose and timing; all trimester exposure is possible |
|
Breastmilk transfer |
CBD detected in human breastmilk in studies examining cannabis-using nursing mothers; CBD-specific breastmilk data limited; lipophilicity means accumulation possible |
Yes — neonatal exposure through breastmilk is documented for cannabis; CBD-specific data limited |
Most breastmilk cannabis data conflates CBD and THC; CBD-specific breastmilk concentration data needs more research |
|
Human observational studies (cannabis in pregnancy, not CBD specifically) |
Cannabis use in pregnancy associated with increased risk of preterm birth, low birth weight, and neurodevelopmental concerns in offspring — primarily attributed to THC component |
THC component primarily; CBD-specific human risk not isolated |
Nearly all human pregnancy data covers mixed THC/CBD cannabis, not CBD-only products; cannot fully separate CBD from THC effects in this data |
|
FDA review (2019) |
FDA concluded insufficient evidence of safety; identified specific concerns from animal research; issued guidance recommending avoidance |
Yes — regulatory conclusion is avoid |
Precautionary regulatory stance reflecting genuine evidence gaps rather than confirmed human harm at supplement doses |
The evidence summary:CBD crosses the placenta. It reaches the developing fetus. The fetal ECS is actively guiding brain development and is sensitive to cannabinoid modulation. Animal studies at high doses show concerning developmental effects. Human data is insufficient to establish safety at any dose. These facts, taken together, fully justify the major medical organizations' recommendation to avoid CBD during pregnancy — not because harm at supplement doses is proven, but because the developing brain is not an appropriate context for uncertainty about an ECS-active compound.
Breastfeeding presents a distinct situation from pregnancy — the neonate is no longer in utero, but the developing infant brain remains vulnerable to cannabinoid exposure in the neonatal and early postnatal period. The ECS continues to direct brain development throughout the first years of life.
CBD is lipophilic (fat-soluble), which means it concentrates in fatty tissues — including breastmilk, which has high fat content. A2018 study in Obstetrics & Gynecology measured cannabinoids in human breastmilk from cannabis-using mothers and found detectable cannabinoids in breastmilk samples — with a median transfer of approximately 3.7% of maternal dose to the infant through breastmilk. This study primarily measured THC and THC-COOH, with limited CBD-specific data; but the lipophilicity mechanism applies equally to CBD.
The neonatal liver is also immature — CBD's CYP450 metabolismoperates at lower efficiency in infants than adults, meaning any CBD transferred through breastmilk may have a longer half-life and accumulate to higher relative concentrations in the infant system. This combination — lipophilic transfer through breastmilk + immature infant metabolism — justifies the precautionary recommendation against CBD during breastfeeding.
The question of CBD in pregnancy doesn't arise from recklessness — it arises because pregnancy produces symptoms that are genuinely difficult to manage, for which conventional options are often limited or have their own safety concerns. Understanding what drives the question helps provide better answers:
|
Pregnancy Symptom |
Evidence-Based Non-CBD Alternative |
Notes |
|
Nausea / morning sickness |
Vitamin B6 (pyridoxine) — FDA category A; ginger supplements or tea; doxylamine (Unisom) + B6 (Diclegis) for moderate-severe nausea |
First-line for pregnancy nausea; discuss with OB for severe hyperemesis gravidarum |
|
Sleep difficulty |
Sleep hygiene, pregnancy pillow positioning, magnesium glycinate (generally considered safe in pregnancy — discuss dose with OB), CBT-I techniques |
Avoid melatonin at high doses in pregnancy — evidence on safety is limited; discuss with OB |
|
Anxiety |
CBT, mindfulness-based interventions, prenatal yoga, support groups, social support; SSRIs (physician-directed) for clinical anxiety |
Anxiety in pregnancy is common; physician-supervised CBT is first-line; medication decisions are OB-guided |
|
Back pain and musculoskeletal |
Physical therapy, prenatal massage (from certified therapist), swimming, gentle yoga, acetaminophen (low dose, discussed with OB) |
Avoid topical CBD; acetaminophen recent safety questions also — all analgesics in pregnancy require OB guidance |
|
Inflammatory symptoms |
Rest, ice/heat therapy, appropriate physical activity; omega-3 fatty acids (generally safe in pregnancy for anti-inflammatory benefit) |
NSAIDs are contraindicated in pregnancy (especially third trimester); physician-directed management |
|
General stress / mood |
Prenatal mindfulness, exercise (as approved by OB), adequate social support, therapy, prenatal vitamins |
Postpartum depression and perinatal anxiety are medical conditions — physician involvement essential |
The safety concerns for CBD during pregnancy and breastfeeding are specific to fetal and neonatal ECS vulnerability and placental/breastmilk transfer. These concerns do not extend to the period after breastfeeding has concluded.
Once breastfeeding ends, CBD's safety profile returns to the standard adult assessment — favorable at typical doses for healthy adults, with the standard considerations for medication interactions and medical conditions covered elsewhere in this library. The postpartum period, specifically, presents its own distinct context with its own mental health considerations — seeCBD for Postpartum Anxiety: What You Need to Know for the post-breastfeeding CBD picture, including the appropriate timing for reintroduction and the postpartum-specific applications where CBD's evidence is strongest.
No trimester is considered safe for CBD use during pregnancy by the FDA, ACOG, or major medical organizations. The first trimester is actually the most critical period for organogenesis — the formation of the fetal brain and organs — when ECS-directed development is at its most foundational. CBD should be avoided throughout pregnancy, regardless of trimester.
Topical CBD is not recommended during pregnancy. While topical application produces lower systemic absorption than oral CBD, it is not zero — particularly with nano-optimized formulations designed for enhanced skin penetration. The precautionary principle applies to all routes of administration during pregnancy, given the fetal ECS sensitivity and absence of topical-specific safety data in pregnant individuals.
This is a common and understandable concern. First, the evidence of harm from brief CBD exposure in early pregnancy (before recognition) is not established — the precautionary guidance is prospective (for known pregnancies) rather than a certainty of harm from early unintended exposure. Discontinue CBD as soon as pregnancy is confirmed, and discuss the specific situation with your obstetrician. Most OBs will provide appropriate reassurance for brief early exposure while confirming discontinuation going forward.
The precautionary recommendation is to discontinue CBD before conception attempts given the uncertainty about periconception exposure and early implantation-period ECS sensitivity. Endocannabinoid signaling plays a role in implantation — the CBD-FAAH inhibition mechanism alters anandamide tone, and anandamide is involved in uterine implantation. The clinical significance of this for fertility is not established, but the precautionary principle applies to the preconception period as well. Discuss with your reproductive endocrinologist or OB.
Hemp seed oil (pressed from hemp seeds, not extracted from the flower) contains minimal CBD or other cannabinoids and is used as a food oil — it is generally considered safe in pregnancy as a food ingredient. This is distinct from hemp extract/CBD oil derived from hemp flowers. Hemp tea prepared from hemp leaves and stems (not flowers) also contains very low cannabinoid levels. However, any product marketed as 'CBD tea' or 'hemp extract' should be avoided during pregnancy.
The recommendation is unambiguous: avoid CBD during pregnancy and breastfeeding. CBD crosses the placenta. The fetal endocannabinoid system actively directs brain development. Animal research shows concerning effects from prenatal cannabinoid exposure. Human safety data at any dose during pregnancy does not exist. The FDA and ACOG both advise avoidance.
The symptoms that drive pregnant people to search for CBD — nausea, anxiety, sleep disruption, pain — are real and deserve real answers. Those answers exist in the form of evidence-based, pregnancy-safe interventions. The alternatives table above and conversations with your obstetrician are the appropriate resources, not supplements with unestablished pregnancy safety.
After pregnancy, after breastfeeding ends, CBD's favorable safety profile returns. That is the appropriate time to explore PureCraft's products — with your physician's awareness and the full benefit of the evidence base behind CBD in healthy adults.
PREGNANCY SAFETY NOTICE | PREGNANCY SAFETY NOTICE:PureCraft CBD products are not intended for use during pregnancy or breastfeeding. The FDA and ACOG advise against CBD use during pregnancy and lactation. CBD crosses the placenta and reaches the developing fetus. The fetal endocannabinoid system is actively involved in brain development and is sensitive to cannabinoid modulation. Safety of CBD at any dose during pregnancy has not been established. If you are pregnant, breastfeeding, or planning to conceive, consult your obstetrician before using any supplement. This article is for informational purposes only and does not constitute medical advice.
Medical Disclaimer | Sauna use is contraindicated in certain cardiovascular conditions, pregnancy, and with medications that impair heat tolerance...
Read More
Medical Disclaimer | Cold water immersion is contraindicated in people with cardiovascular conditions, Raynaud's disease, hypertension, or cold ur...
Read More
Medical Disclaimer | This article is for informational and educational purposes only. Intermittent fasting and CBD supplementation should be appro...
Read More